The DOI matches its Crossref record.
Intraocular Pressure–Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy Volunteers
Abstract
OBJECTIVE: To investigate the effects and safety of topical administration of an ophthalmic solution of a selective Rho-associated coiled coil-forming protein kinase (ROCK) inhibitor, SNJ-1656, 0.003% to 0.1%, in healthy male adult volunteers. DESIGN: Randomized, double-masked, group-comparison, phase 1 clinical study. In the initial single-instillation trial, 45 healthy volunteers were randomly subdivided into 5 groups and treated with SNJ-1656 in concentrations of 0.003%, 0.01%, 0.03%, 0.05%, and 0.1% in stepwise fashion. In the repeated-instillation trial, 36 healthy volunteers were assigned to receive SNJ-1656 ophthalmic solution at the following concentrations and dosages: 0.05% once daily, 0.1% once daily, 0.05% twice daily, or 0.1% twice daily. In our studies, the administration of the solution and subsequent examinations (including intraocular pressure [IOP] measurements) were performed in a double-masked fashion. RESULTS: After single instillation of placebo or SNJ-1656, in concentrations of 0.003%, 0.01%, 0.03%, 0.05%, and 0.1%, the changes in IOP from the baseline were -0.91, -1.18, -1.48, - 2.20 (P = .04 vs placebo), -1.48, and -1.98 mm Hg, respectively, at 2 hours, and -0.63,-0.95, -1.79, -2.26 (P = .01 vs placebo), -1.95, and -3.00 mm Hg (P < .001 vs placebo) respectively, at 4 hours. Significant IOP reductions after repeated instillation were also found. On slitlamp examination during the trial, there were no significant adverse findings except hyperemia of the bulbar and palpebral conjunctiva after instillation. CONCLUSION: This clinical study demonstrated that SNJ-1656 is a safe topical agent effective in reducing IOP in human eyes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential
Feng, Y., LoGrasso, P. V., Defert, O., & Li, R. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00683 · Cited by 378
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna, A. P., & Johnson, M. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.040 · Cited by 257
Beydoun, T., Deloche, C., Perino, J., Kirwan, B.-A., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0247 · Cited by 39
Inoue-Mochita, M., Inoue, T., Fujimoto, T., Kameda, T., Awai-Kasaoka, N., Ohtsu, N., Kimoto, K., & Tanihara, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120774 · Cited by 34
Self-citation
Metadata
- Authors
- Tanihara, H.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2008-03-01
- Volume
- 126
- Issue
- 3
- Pages
- 309
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2060999873
- Cited by
- 163
- References
- 0
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intraocular Pressure–Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy Volunteers. https://app.cochat.ai/papers/10.1001/archophthalmol.2007.76
- The paper
- Tanihara, H. (2008). Intraocular Pressure–Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy Volunteers. Archives of Ophthalmology. https://doi.org/10.1001/archophthalmol.2007.76
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.